Top

Published in:

01-03-2007 | Original Article

Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat

Authors: Slawomir A. Mucha, Gabriela Meleń-Mucha, Andrzej Godlewski, Henryk Stepień

Published in: Virchows Archiv | Issue 3/2007

Abstract

The development of estrogen-induced pituitary prolactinoma in Fischer 344 (F344) rats is associated with enhanced neovascularization. Based on the significance of matrix metalloproteinases (MMPs) for tumor growth and angiogenesis, we have studied the effect of batimastat (BB-94), a synthetic MMPs inhibitor (MMPI) on the progression of prolactin-secreting pituitary adenoma in rats. Pituitary tumors were induced in male F344 rats by s.c. implantation of Silastic tubes containing diethylstilbestrol (DES). The effects of chronic treatment with BB-94 (30 mg/kg b.w.) on pituitary weight, cell proliferation, apoptosis and vascular density were evaluated. We have stated that chronic treatment with batimastat caused a significant reduction in the pituitary weight. Batimastat has been found to decrease cell proliferation evaluated by a number of PCNA-positive stained cell nuclei. A marked increase in the apoptotic index within the pituitary was observed in the study group. Moreover, the density of microvessels identified by CD31 was reduced in the group treated with BB-94. The results of our study provide evidence for an inhibitory effect of batimastat, a synthetic MMPI, on the growth and angiogenesis in an experimental model of human prolactinoma. The ability of BB-94 to suppress established pituitary tumor growth suggests a possible application of MMPIs in the treatment of pituitary adenomas.

Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798–827PubMedCrossRef

Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Beliveau R (1999) Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45:1432–1441PubMedCrossRef

Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220–240PubMedCrossRef

Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326:515–517PubMedCrossRef

Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition—a review of anti-tumor activity. Ann Oncol 6:967–974PubMed

Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciano A, Brown PD, Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464PubMedCrossRef

Davies B, Brown P, East N, Crimmin MJ, Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087–2091. Erratum: Cancer Res 53:3652PubMed

DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671–677PubMed

Elias KA, Weiner RI (1984) Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549–4553PubMedCrossRef

10.

Farnoud MR, Farhadian F, Samuel JL, Derome P, Peillon F, Li JY (1995) Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int J Cancer 61:27–34PubMedCrossRef

11.

Farnoud MR, Veirana N, Derome P, Peillon F, Li JY (1996) Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Int J Cancer 67:45–53PubMedCrossRef

12.

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRef

13.

Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356–5364PubMed

14.

Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501PubMedCrossRef

15.

Heath EI, Grochow LB (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59:1043–1055PubMedCrossRef

16.

Jugenburg M, Kovacs K, Jugenburg I, Scheithauer BW (1998) Angiogenesis in endocrine neoplasms. Endocr Pathol 8:259–272

17.

Katznelson L, Alexander JM, Klibanski A (1993) Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76:1089–1094PubMedCrossRef

18.

Knox JD, Bretton L, Lynch T, Bowden GT, Nagle RB (1998) Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 35:248–254PubMedCrossRef

19.

Lei H, Kalluri R, Furth EE, Baker AH, Strauss JF 3rd (1999) Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. Biol Reprod 60:176–182PubMedCrossRef

20.

Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, Winkelmann B, Schnorr D, Loenings SA (2000) Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 43:77–82PubMedCrossRef

21.

Levy A (1999) Mitosis and apoptosis in anterior pituitary gland: tumour formation or hyperplasia? Baillieres Best Pract Res Clin Endocrinol Metab 13:353–365PubMedCrossRef

22.

Meleń-Mucha G, Winczyk K, Pawlikowski M (1998) Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res 18:3615–3620PubMed

23.

Minderman T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364

24.

Murphy G, Docherty AJP (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120–125PubMed

25.

Páez Pereda M, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Müller A, Renner U, Podhajcer O, Arzt E, Stalla GK (2000) High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 85:263–269PubMedCrossRef

26.

Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500–509PubMed

27.

Pereda MP, Goldberg V, Chervin A, Carizzo G, Molina A, Andrada J, Sauer J, Renner U, Stalla GK, Arzt E (1996) Interleukin-2 (IL-2) and IL-6 regulate c-fos protooncogene expression in human pituitary adenoma explants. Mol Cell Endocrinol 124:33–42PubMedCrossRef

28.

Phelps C, Hymer WC (1983) Characterization of oestrogen-induced adenohypophyseal tumors in the Fischer 344 rat. Neuroendocrinology 37:23–31PubMed

29.

Sang QX (1998) Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8:171–177PubMed

30.

Schechter J, Ahmad N, Elias K, Weiner R (1987) Estrogen-induced tumors: changes in the vasculature in two strains of rat. Am J Anat 179:315–323PubMedCrossRef

31.

Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733–744PubMedCrossRef

32.

Sledge GW Jr, Qulali M, Goulet R, Bone EA, Fife R (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546–1550PubMedCrossRef

33.

Spady TJ, McComb RD, Shull JD (1999) Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland. Endocrine 11:217–233PubMedCrossRef

34.

Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R (2000) Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 11:341–352PubMedCrossRef

35.

Stepień H, Grochal M, Zieliński KW, Mucha S, Kunert-Radek J, Kulig A, Stawowy A, Pisarek H (1996) Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99–106PubMedCrossRef

36.

Talbot DC, Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32:2528–2533CrossRef

37.

Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293–298PubMedCrossRef

38.

Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JAH (2000) Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85:2931–2935PubMedCrossRef

39.

Turner HE (2001) Pituitary tumor angiogenesis. Endocrinologist 11:465–469

40.

Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726–4728PubMed

41.

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef

42.

Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180PubMedCrossRef

43.

Wiklund J, Wertz N, Gorski J (1981) A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocrinology 109:1700–1707PubMedCrossRef

44.

Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154PubMed

45.

Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193–202PubMedCrossRef

46.

Wyllie AH (1993) Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205–208PubMed

47.

Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997) Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367–371PubMedCrossRef

Title: Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat
Authors: Slawomir A. Mucha
Gabriela Meleń-Mucha
Andrzej Godlewski
Henryk Stepień
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 3/2007
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-006-0351-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Co-expression of EGF receptor, TGFα and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis

Expression of transcription factors and precursor cell markers during regeneration of β cells in pancreata of rats treated with streptozotocin

Extrauterine endometrial stromal sarcoma with JAZF1/JJAZ1 fusion confirmed by RT-PCR and interphase FISH presenting as an inguinal tumor

MYH, OGG1, MTH1, and APC alterations involved in the colorectal tumorigenesis of Korean patients with multiple adenomas

Announcements

Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer